MMP9 and non-small cell lung carcinoma: Increased levels of MMP9 in turn were linked to metastasis and reduced survival rates in lung AD patients, strongly suggesting that inhibiting the MSC-NSCLC crosstalk through inhibiting the ABL kinase-MMP9 signaling axis could be a potential target to reduce (MSC-induced) NSCLC metastasis [39].